Accessibility StatementSkip Navigation About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Attorney Advertising. Past results do not guarantee a similar outcome. SOURCE Robbins LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- ...

Takeda (NYSE: TAK ) is currently a unique biopharma case that may lead to opportunities for investors. While the company is facing significant valuation issues, particularly after the costly Shire acquisition, the company has performed deft kaizen to improve their pipeline. In fact, Takeda hasHello, I am an individual investor with an interest in bringing diversification of viewpoints to stock analysis and investing. This brings to point the Japanese proverb 他山之石 -ta-zan-no-ishi- which translates to "anothe ...

Transaction expected to close on October 7, 2025LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by Merck & Co., Inc. (NYSE: MRK) (“Merck”) through a wholly owned subsidiary or a nominee, today announced that its shareholders have approved the proposal for Merck to acquire Verona Phar ...

NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013. “We are happy to have Dr. Bolno join our Board at this critical moment while we transition toward a future focused on helping large populations avoid becoming il ...

公司战略活动 - 公司将于2025年10月8日举办分析师与投资者活动，提供战略更新 [1] - 活动将在纽约市举行，并通过网络直播进行，时间为美国东部时间上午11:30至下午2:00 [1] - 活动议程包括公司管理层演讲以及代谢功能障碍相关脂肪性肝炎领域主要意见领袖和患者代表的见解 [2][5] 核心产品管线 - 公司主要资产为lanifibranor，一种用于治疗代谢功能障碍相关脂肪性肝炎的新型泛PPAR激动剂 [3] - 该药物正处于关键的NATiV3三期临床试验阶段，预计将在2026年下半年公布顶线结果 [5] - 活动将深入探讨lanifibranor的作用机制、二期临床试验的关键发现以及三期试验的设计与进展 [6] 行业专家参与 - 活动将邀请多位国际知名专家参与，包括哈佛医学院医学教授Nezam Afdhal博士 [6] - 伦敦玛丽女王大学肝病学教授兼研究主任William Alazawi博士也将出席 [6] - 三期NATiV3研究的共同主要研究者、弗吉尼亚联邦大学医学院的Arun Sanyal博士将参与讨论 [6] 市场定位与潜力 - 活动将讨论lanifibranor在巨大的全球代谢功能障碍相关脂肪性肝炎市场中的预期定位 [6] - 将重点介绍该药物因其独特的肝内和肝外双重活性，如何满足代谢功能障碍相关脂肪性肝炎治疗领域未满足的关键需求 [6] - 专家将阐述影响代谢功能障碍相关脂肪性肝炎治疗格局的关键趋势 [5]

公司概况 - 公司为专注于发现、开发和商业化专有治疗药物的生物制药企业 在肿瘤学及其他严重疾病领域拥有创新疗法[1] - 公司在行业中与大型制药公司竞争 通过战略领导和产品开发维持市场地位[1] 评级与股价表现 - RBC Capital于2025年9月24日将评级调整为"行业表现" 维持持有建议 同时将目标价从72美元上调至81美元[2] - 当前股价84.49美元 较前日下跌0.05美元（跌幅0.06%） 日内交易区间为84美元至84.72美元[4] - 过去52周股价波动区间为53.56美元至87.99美元 显示较大波动性[4] 管理层变动 - 公司任命Dave Gardner为执行副总裁兼首席战略官 该举措旨在加强领导团队建设[3] - 此次任命体现公司通过增强高管团队支持业务目标的战略承诺[3] 市场数据 - 公司市值约165亿美元 在生物制药行业具有重要市场地位[5] - 当日交易量为58,964股 显示中等投资者关注度[5]

股价表现 - 公司股价今日迄今上涨13% [3] 分析师评级与核心资产 - Stifel将公司评级从持有上调至买入 [3] - 评级上调源于对公司长期潜力信心增强 主要基于其核心资产telitacicept的前景 [3]

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025. Cytokinetics describes itself as a "biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in- class muscle inhibitors as potential treatments for debilitating diseases in which muscl. ...

Zacks Premium服务 - 提供Zacks Rank和Zacks Industry Rank每日更新服务 [1] - 包含Zacks 1 Rank List、股票研究报告和高级选股筛选器 [1] - 提供Zacks Style Scores评分系统作为投资辅助工具 [1] Style Scores评分体系 - 采用字母评级系统(A/B/C/D/F)评估股票价值、成长和动量特性 [3] - 价值评分基于P/E、PEG、Price/Sales等比率识别折价股票 [3] - 成长评分综合预测和历史收益、销售额及现金流指标 [4] - 动量评分利用周价格变动和盈利预测月变化等因子 [5] - VGM评分整合所有风格评分形成综合指标 [6] 评分与排名协同应用 - Zacks Rank 1(强力买入)股票自1988年来年均回报达+23.64% [7] - 每日有超过200家Strong Buy和600家Buy评级公司 [8] - 建议优先选择Zacks Rank 1/2且Style Scores A/B的组合 [9] - 即使评分优异，4(Sell)或5(Strong Sell)评级股票仍存在下行风险 [10] Alnylam Pharmaceuticals案例 - 公司专注于RNA干扰技术治疗药物开发 [11] - 2018年Onpattro获美欧批准治疗hATTR淀粉样变性 - 2019年Givlaari获FDA批准治疗急性肝卟啉症 - 2020年Oxlumo获批治疗原发性高草酸尿症1型 - 2022年Amvuttra获FDA和EC批准并扩展适应症 - 当前Zacks Rank 3(Hold)评级且VGM评分B级 [12] - 动量评分A级，过去四周股价上涨0.7% [12] - 10位分析师60天内上调2025财年盈利预测2.06美元 [12] - 共识预期升至每股3.66美元，平均盈利惊喜达+348.4% [12]

ALAMEDA, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it will present at the Emerging Growth Conference 86 on September 25, 2025. Vivani welcomes individual and institutional investors, along with advisors and analysts, to join its interactive presentation. This live online event will offer existing shareholders and the investme ...